Abstract
Rabeprazole (RPZH) (available as rabeprazole sodium, RPZNa) is a proton pump inhibitor (PPI), widely used for the treatment of acid-related diseases in the stomach and duodenum. It is a weak base with pKa= 4.9 and show a strong ability to form complexes with transition and nontransition metal ions. Its complexes with Cu(II), Zn(II), Cd(II) and Hg(II) have been synthesized and characterized by solubility, melting point, metal content estimation, IR and UV-Visible spectral analysis, magnetic measurement, thermogravimetric analysis, differential scanning calorimetry and X-ray powder diffraction studies. On the basis of metal contents, the complexes have been formulated as [Cu(RPZ)(H2O)Cl], [Zn(RPZ)2], [Cd(RPZ)2].2H2O and [Hg(RPZ)2].H2O. Rabeprazole sodium (RPZNa) loses Na+ ion in solution yielding a monoanionic RPZ that behaves as a bidentate ligand and coordinates through C-N- and S=O groups with the divalent metal ion. Tetrahedral geometry of all complexes is proposed. Zn(II), Cd(II) and Hg(II) complexes have 1:2 metal to ligand stoichiometry while Cu(II) complex possesses ligand to metal ratio of 1:1. Cu(II) and Zn(II) complexes have also been screened for their antibacterial and antifungal activities against several bacteria and fungi.
 Dhaka Univ. J. Sci. 65(2): 157-162, 2017 (July)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
